Three Highlights from North America’s Premier Smoking Cessation Conference

January 2020

Decorative image
Top experts gathered in Ottawa last week to discuss the latest ideas, evidence and research in clinical smoking cessation approaches.

Cannabis, e-cigarettes, and human genetics. Dr. Andrew Pipe interviews key delegates from 2020 conference.  

Last week in the nation’s capital, the world’s most prominent smoking cessation authorities gathered to attend the 12th Annual Ottawa Conference: State-of-the-Art Clinical Approaches to Smoking Cessation, hosted by the University of Ottawa Heart Institute (UOHI).

Quit-smoking leaders from San Francisco to Toronto were in attendance to share the latest ideas, evidence and research related to North America’s leading cause of preventable disease, disability and death – tobacco addiction.

The Beat’s editorial team was on the conference floor to bring you highlights from two days of plenary and breakout sessions, panel discussions, and poster displays.

Hosted by Conference Co-Chair Dr. Andrew Pipe,  himself a highly sought-after smoking cessation leader, here are three video highlights from this year’s Ottawa Conference.

Dr. David Hammond cautions cannabis users away from processed vape oils and high-potency products.

Dr. Hammond is a professor in the School of Public Health and Health Systems at the University of Waterloo. His research focuses on tobacco control, cannabis use and nutrition policies. Hammond works closely with governments around the world and has served as an advisor for the World Health Organization.

Dr. Stanton Glantz says e-cigarettes are like going “Back to the Future.”

Dr. Glantz is an American professor, author, and leading tobacco control activist and recognized e-cigarette expert. He is the director of the University of California San Francisco Center for Tobacco Control Research and Education; a Co-leader of the Helen Diller Family Comprehensive Cancer Center Tobacco Program; and a member of the Cardiovascular Research Institute and Philip R. Lee Institute for Health Policy Studies.

And Dr. Rachel Tyndale explores the link between smoking cessation and human genetics.

Dr. Tyndale is a senior scientist and the head of the Pharmacogenetics Laboratory in the Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health. She is a Canada research chair in pharmacogenomics, and a professor in the Departments of Psychiatry, Pharmacology and Toxicology at the University of Toronto. Through her work, Dr. Tyndale investigates genetic risk factors for drug dependence to better understand the mechanisms involved with drug abuse and to optimize treatment approaches.

Next year’s Ottawa Conference is scheduled for January 21-23, 2021.

Learn more about the Ottawa Model for Smoking Cessation and this year’s Ottawa Conference in this CTV Morning Live interview with UOHI’s Dr. Andrew Pipe.

Share This